Table 1 Patient demographics and characteristics

Sex

 Male

31 (59.6%)

 Female

21 (40.4%)

Age (y)

 Median (25–75%)

11.8 (8.0–15.6)

Time interval between

 MRI and liver biopsy, day, median (25–75%)

1 (0–2)

BMI Z-score, mean ± SD (range)

0.1921 ± 1.4983 (− 3.29  −  + 3.90)

  >  + 2 n (%)

6 (11.5%)

  < − 2 n (%)

2 (3.8%)

Etiology of the liver disease—no. (%)

 Chronic hepatitis of uncertain etiology

14 (26.9%)

 Autoimmune hepatitis

9 (17.3%)

 Chronic viral hepatitis

7 (13.5%)

 Genetic/metabolic disorders

7 (13.5%)

 Cirrhosis of different etiology

5 (9.6%)

 Others

10 (19.2%)

Ishak fibrosis stages, median (25–75%)

2.0 (1.0–3.0)

Stage

 0

3 (5.8%)

 1

15 (28.8%)

 2

10 (19.2%)

 3

13 (25.0%)

 4

6 (11.5%)

 5

1 (1.9%)

 6

4 (7.7%)

Histologic activity index, median (25–75%)

3.0 (2.0–5.0)

 No

1 (1.9%)

 Minimal (1–3 points)

28 (53.8%)

 Mild (4–8 points)

19 (36.5%)

 Moderate (9–12 points)

4 (7.7%)

 Severe (13–18 points)

0 (0%)

Fat/steatosis (n = 51), median (25–75%)

2.9 (2.2–10.9%)

 0 (< 5%)

35 (67.3%)

 1 (5–33%)

15 (28.8%)

 2 (34–66%)

1 (1.9%)

 3 (> 66%)

0 (0.0%)

ALT IU/L, median (25–75%)

69.5 (31.0–176.3)

  > 40 IU/L (%)

36 (69.2%)

AST IU/L, median (25–75%)

79.0 (32.5–183.75)

  > 40 IU/L (%)

35 (67.3%)